Latest News

Sensus Healthcare (NASDAQ:SRTS) Downgraded by B. Riley to “Neutral”

B. Riley lowered shares of Sensus Healthcare (NASDAQ:SRTS) from a buy rating to a neutral rating in a report released on Thursday, Briefing.com Automated Import reports. The brokerage currently has $5.50 price target on the stock, down from their prior price target of $14.00.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.

Several other equities research analysts also recently weighed in on the stock. HC Wainwright restated a buy rating and issued a $10.00 target price on shares of Sensus Healthcare in a research note on Thursday. Maxim Group set a $11.00 target price on shares of Sensus Healthcare and gave the company a buy rating in a research note on Friday, August 9th. ValuEngine downgraded shares of Sensus Healthcare from a buy rating to a hold rating in a research note on Thursday, October 17th. Finally, TheStreet upgraded shares of Sensus Healthcare from a d+ rating to a c- rating in a research note on Monday, August 26th. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating and four have assigned a buy rating to the stock. The stock currently has a consensus rating of Hold and an average target price of $8.30.

Shares of NASDAQ:SRTS traded down $0.21 during trading on Thursday, reaching $3.80. 73,900 shares of the company were exchanged, compared to its average volume of 31,014. The firm has a market capitalization of $93.54 million, a PE ratio of -27.14 and a beta of -0.41. Sensus Healthcare has a 12-month low of $3.71 and a 12-month high of $9.23. The business’s fifty day simple moving average is $5.73 and its 200-day simple moving average is $5.72.

Sensus Healthcare (NASDAQ:SRTS) last announced its earnings results on Wednesday, November 6th. The company reported ($0.04) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.05) by $0.01. The company had revenue of $5.84 million during the quarter, compared to the consensus estimate of $7.77 million. Sensus Healthcare had a negative net margin of 8.65% and a negative return on equity of 8.82%. On average, sell-side analysts expect that Sensus Healthcare will post -0.12 EPS for the current fiscal year.

Several large investors have recently bought and sold shares of SRTS. Wells Fargo & Company MN acquired a new stake in shares of Sensus Healthcare during the second quarter worth $30,000. Susquehanna International Group LLP lifted its stake in shares of Sensus Healthcare by 69.9% during the second quarter. Susquehanna International Group LLP now owns 27,492 shares of the company’s stock worth $152,000 after buying an additional 11,311 shares during the period. Essex Investment Management Co. LLC acquired a new stake in shares of Sensus Healthcare during the third quarter worth $540,000. BlackRock Inc. lifted its stake in shares of Sensus Healthcare by 40.7% during the second quarter. BlackRock Inc. now owns 103,643 shares of the company’s stock worth $574,000 after buying an additional 29,990 shares during the period. Finally, Heartland Advisors Inc. lifted its stake in shares of Sensus Healthcare by 150.0% during the second quarter. Heartland Advisors Inc. now owns 375,000 shares of the company’s stock worth $2,078,000 after buying an additional 225,000 shares during the period. Institutional investors and hedge funds own 9.95% of the company’s stock.

About Sensus Healthcare

Sensus Healthcare, Inc manufactures and markets superficial radiation therapy devices to healthcare providers worldwide. It offers SRT-100, a photon X-ray low energy superficial radiotherapy system that provides patients an alternative to surgery for treating non-melanoma skin cancers; and SRT-100 Vision, which provides the user with a superficial radiation therapy-tailored treatment planning application that integrates the embedded high frequency ultrasound imaging module, volumetric tumor analysis, beam margins planning, and dosimetry parameters.

Featured Article: What does RSI mean?

Analyst Recommendations for Sensus Healthcare (NASDAQ:SRTS)

Leave a Reply

Your email address will not be published. Required fields are marked *